Profile data is unavailable for this security.
About the company
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions.
- Revenue in USD (TTM)0.00
- Net income in USD-7.25m
- Incorporated2009
- Employees16.00
- LocationEdesa Biotech Inc100 Spy CrtMARKHAM L3R 5H6CanadaCAN
- Phone+1 (905) 475-1234
- Fax+1 (905) 475-1234
- Websitehttps://www.edesabiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organovo Holdings Inc | 109.00k | -14.67m | 13.02m | 12.00 | -- | 2.53 | -- | 119.43 | -1.62 | -1.62 | 0.0119 | 0.3573 | 0.0082 | -- | 1.18 | 5,450.00 | -110.05 | -54.25 | -138.86 | -58.42 | -- | -- | -13,459.63 | -1,890.16 | 1.96 | -- | 0.00 | -- | -70.54 | -48.78 | 15.00 | -- | -11.87 | -- |
| GlucoTrack Inc | 0.00 | -8.74m | 13.15m | 6.00 | -- | 34.16 | -- | -- | -1.87 | -1.87 | 0.00 | 0.0703 | 0.00 | -- | -- | 0.00 | -520.58 | -94.01 | -2,110.63 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | 0.3415 | -- | -- | -- | -60.02 | -- | -- | -- |
| Pieris Pharmaceuticals Inc | 40.93m | -16.25m | 13.32m | 46.00 | -- | 0.5681 | -- | 0.3255 | -12.74 | -12.74 | 34.05 | 17.76 | 0.7324 | -- | 28.25 | 889,717.40 | -29.09 | -28.41 | -52.98 | -39.69 | -- | -- | -39.71 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 13.55m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| Cardio Diagnostics Holdings Inc | 33.00k | -11.51m | 13.57m | 7.00 | -- | 4.26 | -- | 411.09 | -0.8257 | -0.8257 | 0.0021 | 0.1404 | 0.0051 | -- | -- | 4,714.29 | -178.70 | -- | -325.81 | -- | -- | -- | -34,872.12 | -- | -- | -4.84 | 0.0715 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
| CV Sciences Inc | 15.86m | -3.23m | 13.65m | 42.00 | -- | 5.78 | -- | 0.8605 | -0.0207 | -0.0207 | 0.1012 | 0.0145 | 1.59 | 1.42 | 27.25 | 377,571.40 | -32.43 | -43.42 | -83.71 | -77.75 | 45.13 | 51.81 | -20.38 | -45.68 | 0.2677 | -13.32 | 0.0472 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
| Nexgel Inc | 4.74m | -3.20m | 14.01m | 19.00 | -- | 2.93 | -- | 2.96 | -0.5535 | -0.5535 | 0.8208 | 0.7688 | 0.4428 | 3.24 | 8.46 | 249,263.20 | -30.72 | -44.61 | -39.92 | -56.19 | 20.14 | 5.02 | -69.38 | -180.98 | 1.41 | -- | 0.1819 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| Flora Growth Corp | 74.78m | -47.58m | 14.10m | 97.00 | -- | 3.15 | -- | 0.1885 | -6.53 | -7.77 | 9.20 | 0.3494 | 1.48 | 5.99 | 23.05 | 770,958.80 | -92.50 | -- | -140.01 | -- | 21.72 | -- | -62.66 | -- | 0.6481 | -- | 0.4952 | -- | 127.75 | -- | -1.87 | -- | -- | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.08m | 14.24m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -7.25m | 14.31m | 16.00 | -- | 3.31 | -- | -- | -2.37 | -2.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -84.50 | -- | -107.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| Galecto Inc | 0.00 | -30.83m | 14.37m | 13.00 | -- | 0.5103 | -- | -- | -1.15 | -1.15 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -63.50 | -48.46 | -78.33 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
| Alaunos Therapeutics Inc | 6.00k | -26.77m | 14.73m | 1.00 | -- | 3.07 | -- | 2,455.25 | -1.67 | -1.67 | 0.0004 | 0.2996 | 0.0002 | -- | 12.00 | 6,000.00 | -97.94 | -74.83 | -147.22 | -89.57 | -- | -- | -446,233.30 | -10,508.06 | -- | -19.25 | 0.00 | -- | -99.83 | -49.08 | 6.86 | -- | -15.56 | -- |
| Nascent Biotech Inc | 0.00 | -2.09m | 14.76m | -- | -- | 483.30 | -- | -- | -0.0147 | -0.0147 | 0.00 | 0.0002 | 0.00 | -- | -- | -- | -346.80 | -815.53 | -- | -- | -- | -- | -- | -548.75 | -- | -- | 0.8045 | -- | -100.00 | -- | -495.46 | -- | -- | -- |
| Mannatech Inc | 127.23m | -1.66m | 15.04m | 213.00 | -- | 1.44 | -- | 0.1182 | -0.899 | -0.899 | 68.07 | 5.54 | 2.77 | 1.93 | 561.74 | 597,342.80 | -3.62 | 4.39 | -9.67 | 9.16 | 78.01 | 77.87 | -1.31 | 1.72 | 0.5584 | -- | 0.1384 | 88.33 | -3.83 | -5.33 | 50.13 | -- | -20.38 | -- |
| Traws Pharma Inc | 226.00k | -18.16m | 15.20m | 16.00 | -- | 2.11 | -- | 67.26 | -0.8641 | -0.8641 | 0.0108 | 0.2853 | 0.0085 | -- | 12.91 | 14,125.00 | -68.21 | -63.43 | -104.99 | -85.72 | -- | -- | -8,033.63 | -3,257.92 | -- | -- | 0.00 | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to Edesa Biotech Inc's reporting currency: US Dollar USD
3.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| CM Management LLCas of 31 Mar 2024 | 62.00k | 1.93% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 15.70k | 0.49% |
| Geode Capital Management LLCas of 31 Mar 2024 | 14.39k | 0.45% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 11.33k | 0.35% |
| Tower Research Capital LLCas of 31 Mar 2024 | 2.07k | 0.06% |
| RBC Dominion Securities, Inc. (Investment Management)as of 31 Mar 2024 | 1.74k | 0.05% |
| Vanguard Global Advisers LLCas of 31 Mar 2024 | 162.00 | 0.01% |
| TD Waterhouse Canada, Inc.as of 31 Mar 2024 | 142.00 | 0.00% |
| Strategic Advisers LLCas of 31 Mar 2024 | 142.00 | 0.00% |
| Fifth Third Bank, NA (Investment Management)as of 31 Mar 2024 | 100.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
